Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

ClinicalTrials.gov ID: NCT01682044

Public ClinicalTrials.gov record NCT01682044. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 17, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Clinical Trial of Rituximab in Combination With Pegfilgrastim in Patients With Indolent B-Cell (CD-20-Positive) Lymphoma

Study identification

NCT ID: NCT01682044
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Roswell Park Cancer Institute; Other
Enrollment: 20 participants

Conditions and interventions

Conditions

Interventions

biopsy Procedure
flow cytometry Other
immunohistochemistry staining method Other
pegfilgrastim Biological
rituximab Biological
western blotting Genetic

Procedure · Other · Biological + 1 more

Eligibility (public fields only)

Age range: 19 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 16, 2007
Primary completion: Nov 21, 2013
Completion: Dec 21, 2016
Last update posted: Oct 8, 2017

2007 – 2016

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Roswell Park Cancer Institute	Buffalo	New York	14263	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01682044, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 8, 2017 · Synced May 17, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01682044 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →